Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.35 USD
+0.06 (1.82%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $3.34 -0.01 (-0.30%) 7:58 PM ET
1-Strong Buy of 5 1
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.35 USD
+0.06 (1.82%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $3.34 -0.01 (-0.30%) 7:58 PM ET
1-Strong Buy of 5 1
C Value D Growth D Momentum D VGM
Zacks News
Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the fourth quarter of 2020.
What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?
by Zacks Equity Research
Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.
Myriad Genetics' (MYGN) Prolaris Test Study Outcome Favorable
by Zacks Equity Research
Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.
Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.
Atea Pharmaceuticals (AVIR) Jumps: Stock Rises 9.5%
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.